Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ipilimumab: Preliminary Phase II data

Top-line data from the double-blind Phase II 022 trial showed that ipilimumab had dose-dependent effects. Patients received 0.3,

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE